4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.
Leeds, GB
Size (employees)
24 (est)
4D Pharma is headquartered in Leeds, GB
Report incorrect company information

4D Pharma Office Locations

4D Pharma has an office in Leeds
Leeds, GB (HQ)
9 Bond St
Show all (1)
Report incorrect company information

4D Pharma Financials and Metrics

4D Pharma Financials


Net income (FY, 2016)

(9.9 m)

EBITDA (FY, 2016)

(11.7 m)

EBIT (FY, 2016)

(12.3 m)

Market capitalization (2-Oct-2017)

239.1 m

Closing share price (2-Oct-2017)


Cash (5-Mar-2018)

68.8 m
4D Pharma's current market capitalization is £239.1 m.
GBPFY, 2014FY, 2015FY, 2016


(3.4 m)(10.3 m)(11.7 m)


(3.5 m)(10.5 m)(12.3 m)

Pre tax profit

(2.4 m)(10.1 m)(11.7 m)

Income tax expense

2.3 m1.8 m
GBPFY, 2014FY, 2015FY, 2016


31.8 m85.4 m68.8 m


115 k28 k238 k

Current Assets

32.5 m90.1 m75 m


417 k1.1 m3.9 m
GBPFY, 2014FY, 2015FY, 2016

Net Income

(2.4 m)(7.7 m)(9.9 m)

Cash From Operating Activities

(3.8 m)(9.1 m)(13.5 m)

Cash From Financing Activities

36.7 m63.8 m

Net Change in Cash

28.8 m(27 m)26.9 m
GBPY, 2016

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information